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Background:  Inflammatory response has been implicated in homograft failure in children, and ibuprofen has been postulated to mitigate 
this effect. We investigated the effect of a 3-month postoperative ibuprofen regimen on durability of homografts in the right ventricular 
outflow tract (RVOT) in our institution.
methods:  We began using prophylactic ibuprofen (5 mg/kg/dose 3 times daily for 3 mos) in 2008. We retrospectively reviewed our surgical 
database for patients 4 yrs prior to and 4 yrs after the introduction of this policy. Patients without follow-up after living to discharge were 
excluded from analysis. Data was analyzed with Wilcoxon analysis of Kaplan Meier curves, and significance is defined as p<0.05.
results:  174 patients met inclusion criteria. 103 patients received ibuprofen by intent-to-treat analysis and 71 did not. There were no 
statistically significant differences between groups’ age, gender, body surface area, conduit type and conduit size. Median follow-up was 
19.7 months (interquartile range 11.4 - 46.2 mos) for patients who received ibuprofen, and 57.1 months (interquartile range 13.2 - 92.3 
mos) for those who did not (p<0.05). Conduit failure (defined as need for conduit exchange) occurred in 7%, 15%, and 18% at 1, 3, and 
5 years postoperatively for patients receiving ibuprofen; compared with 10%, 31%, and 33% at 1, 3, and 5 years for those who did not 
receive ibuprofen (p=0.03). Grafts placed orthotopically (i.e. Ross procedures) lasted longer than heterotopically placed grafts (e.g. Rastelli 
or tetralogy of Fallot repairs), with 4% failure rate vs 27% failure rate at 3 years (p=0.009). Aortic homografts had inferior durability (failure 
rate 32%, 52% at 3 and 5 years) compared with pulmonary homografts (failure rate 19% and 21% at 3 and 5 years) (p=0.005).
Conclusion:  A prophylactic regimen using ibuprofen in the early postoperative period after homograft placement in the RVOT may prolong 
conduit survival.
